Moderna vs Pfizer: Which Is the Better Buy in 2026?

Pfizer has 15+ drugs generating meaningful revenue across multiple therapeutic areas — COVID was extraordinary and non-recurring, but the underlying pharmaceutical business is substantial. Moderna's revenue remains concentrated in COVID and now RSV vaccines, with a pipeline that represents future potential rather than current diversification. The risk profile difference is significant: Pfizer can absorb a pipeline miss because other programs carry the business; Moderna's next key trial readout matters more.

Pfizer's post-COVID normalization is the more complex story, but its pipeline diversification provides significantly more cushion than Moderna's. Pfizer earns from oncology, rare diseases, RSV vaccines, and hospital products that continue regardless of COVID revenue — the Paxlovid and vaccine cliff is real, but the rest of the business still runs. Moderna is more dependent on its mRNA technology platform, and while its pipeline has expanded meaningfully into influenza, RSV, and cancer vaccines, most of those programs are 2–4 years from meaningful revenue. Pfizer for current cash flow and pipeline breadth; Moderna for higher upside if mRNA becomes the dominant vaccine technology platform.